Description

Portalak (lactulose) syrup 667 mg/ml. 500 ml. №1 vial

Ingredients

Active ingredient: Lactulose 667 mg/ml.

Dosage

Dosage: The usual adult dose is 15-30 ml daily, adjusted according to individual response.

Indications

Indications: Portalak syrup is indicated for the treatment of constipation and hepatic encephalopathy.

Contraindications

Contraindications: Do not use in patients with galactosemia or a history of intestinal obstruction.

Directions

Directions: Take orally. Can be taken with water, juice, or milk. It may take 1-2 days to show effect.

Scientific Evidence

Lactulose, the active ingredient in Portalak syrup, works by drawing water into the colon, softening the stool and increasing bowel movements. Studies have shown that lactulose is effective in treating chronic constipation and hepatic encephalopathy. Research published in the “Journal of Gastroenterology and Hepatology” demonstrated the efficacy of lactulose in improving symptoms of hepatic encephalopathy by reducing ammonia levels in the blood.

Additional Information

Portalak syrup is well-tolerated and has minimal side effects. It is commonly used in clinical practice due to its effectiveness in managing constipation and hepatic encephalopathy. It is important to follow the recommended dosage and consult a healthcare provider for proper guidance on its use.

Pharmacological Effects: Lactulose is a synthetic disaccharide that is not absorbed in the small intestine but is fermented in the colon by the gut microbiota. This fermentation process leads to the production of short-chain fatty acids and lactic acid, which acidify the colonic contents, promoting the growth of beneficial bacteria and softening the stool.

Clinical Trials: Clinical trials have shown that lactulose is effective in improving stool frequency and consistency in patients with chronic constipation. A study published in the “American Journal of Gastroenterology” found that lactulose significantly increased the number of bowel movements per week and improved overall quality of life in constipated patients.